Glycan Sequencing Market

By Sequencing Type;

Hydrazinolysis and Alkaline Borohydride Treatment

By Application;

Glycobiology, Proteomics, Neurobiology, Developmental Immunology, Biotherapeutics, and Antibody Production

By End User;

Research centers, Academic Institutes, Diagnostic Centers, and Cancer Research Labs

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn140493362 Published Date: June, 2025 Updated Date: July, 2025

Glycan Sequencing Market Overview

Glycan Sequencing Market (USD Million)

Glycan Sequencing Market was valued at USD 333.18 million in the year 2024. The size of this market is expected to increase to USD 649.27 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 10.0%.


Glycan Sequencing Market

*Market size in USD million

CAGR 10.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)10.0 %
Market Size (2024)USD 333.18 Million
Market Size (2031)USD 649.27 Million
Market ConcentrationMedium
Report Pages341
333.18
2024
649.27
2031

Major Players

  • Merck & Co Inc
  • Charles River
  • Sciex
  • New England Biolabs
  • Lake Pharma Inc
  • Biocompare
  • Promega Corporation

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Glycan Sequencing Market

Fragmented - Highly competitive market without dominant players


The Glycan Sequencing Market is experiencing robust interest as glycomics technologies gain prominence across biotechnology and pharmaceutical sectors. With over 60% adoption among biopharmaceutical research labs, this market is being driven by the demand for high-throughput and accurate glycan profiling tools. Growing interest in understanding protein-glycan interactions has opened new opportunities for therapeutic and diagnostic advancements. The increasing role of glycan sequencing in immunology and oncology is also pushing forward innovation and research collaborations.

Technological Innovations and Analytical Advancements
Rising adoption of mass spectrometry and advanced chromatography in glycan analysis has transformed the sequencing workflows. Over 55% of glycan studies now integrate next-generation sequencing with high-resolution mass spec platforms to improve structure determination accuracy. These technological advancements have not only improved detection sensitivity but also facilitated expansion into new research domains. Investments in automating glycan libraries and AI-based interpretation systems are helping drive growth in laboratory capabilities.

Opportunities for Expansion Across Therapeutics
The application of glycan sequencing is expanding across biotherapeutics, including monoclonal antibodies and vaccine development, where more than 58% of development pipelines now include glycan analysis. This is creating valuable opportunities to improve product quality, safety, and efficacy through better glycoform profiling. Demand is also rising in precision medicine, pushing companies to adopt strategies centered on biomarker discovery and individualized glycan diagnostics.

Future Outlook Driven by Data Integration
The future of the market lies in integrating glycan sequencing data with multi-omics platforms, which is being adopted by over 52% of research institutions. This approach enhances biological understanding and supports predictive modeling for disease characterization. With the growing focus on data-driven therapeutics, the market is set for further expansion, backed by continued merger and acquisition activity and strategic investment in AI-enabled sequencing platforms. The emphasis on scalability and reproducibility is expected to sustain long-term growth and innovation.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Sequencing Type
    2. Market Snapshot, By Application
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Glycan Sequencing Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Technological Advancements
        2. Increasing Research Interest
        3. Expanding Applications
      2. Restraints
        1. Complexity and Cost
        2. Regulatory Challenges
        3. Limited Awareness
      3. Opportunities
        1. Rising Demand in Emerging Markets
        2. Collaborations and Partnerships
        3. Customized Solutions
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Glycan Sequencing Market, By Sequencing Type, 2021 - 2031 (USD Million)
      1. Hydrazinolysis
      2. Alkaline Borohydride Treatment
    2. Glycan Sequencing Market, By Application, 2021 - 2031 (USD Million)
      1. Glycobiology
      2. Proteomics
      3. Neurobiology
      4. Developmental Immunology
      5. Biotherapeutics
      6. Antibody production
    3. Glycan Sequencing Market, By End User, 2021 - 2031 (USD Million)
      1. Research Centers
      2. Academic Institutes
      3. Diagnostic Centers
      4. Cancer Research Labs
    4. Glycan Sequencing Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Merck & Co Inc
      2. Charles River
      3. Sciex
      4. New England Biolabs
      5. Lake Pharma Inc
      6. Biocompare
      7. Promega Corporation
  7. Analyst Views
  8. Future Outlook of the Market